Transgenic Group

Basic Information

Stock Code
2342
Industry
Services
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Fukuoka Prefecture
Establishment Year
April 1998
Listing Year
December 2002
Official Website
https://www.transgenic.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kojin Bio, Linical, Sōiken HD, Wedge HD, Shin Nihon Kagaku, DNA Chip Research Institute, H.U. Group Holdings, Falco Holdings, BML, Tri-I's, Human Metabolome Technologies, PhoenixBio

Overview

Transgenic Group is a company established in 1998 with its base in Fukuoka, centering on the production of mice for genetic analysis and having established a solid position in the bio-pharmaceutical services industry.

Current Situation

Transgenic Group develops the production of mice for genetic analysis and related services, earning high acclaim in the research and development support market. It actively adopts the latest gene editing technologies and focuses on developing cutting-edge model animals. Estimated sales for fiscal 2023 are on the scale of 2 billion yen, supported by a stable contract business foundation. Compared to competitors, its strengths lie in high-quality mouse models and proprietary technologies, which are widely accepted by customers. It emphasizes environmental considerations and has established a research system attentive to animal welfare. In the medium to long term, it aims to strengthen research and development in gene modification technologies and contribute to the development of new therapies. It promotes active academic collaborations both domestically and internationally to meet diverse needs in bio-pharmaceuticals. Toward 2025, its strategy involves diversifying services and expanding revenue through the introduction of new technologies. It is solidifying its growth foundation based on industry reliability and technological prowess.

Trivia

Interesting Facts

  • Possesses one of Japan's leading technologies for transgenic mouse production.
  • Fukuoka base functions as a hub for Kyushu region's biomedical industry.
  • Commercialized Japan's first conditional knockout mouse.
  • Significantly shortened production time after introducing CRISPR/Cas9 technology.
  • Also supplies model animals to overseas markets such as the US.
  • Leader in the industry regarding ethics of animal experimentation.
  • Regularly holds educational training programs for research institutions.
  • Well-received model information provision via proprietary database management.
  • Holds multiple patents for specific gene-modified models.
  • Promotes industry-academia collaboration projects with local universities and companies.
  • Also focusing on supporting clinical applications of latest genome editing technologies.
  • Domestic top-class number of outsourced special model mouse productions.
  • Numerous speaking invitations related to gene modification technology.
  • Outsourced analysis cases in 2023 increased 10% year-over-year.
  • Collaborative research system utilizing global network.

Hidden Connections

  • Holds multiple undisclosed partnerships with domestic and international pharmaceutical development companies.
  • Secretly operates technology support business for university-spinoff venture companies.
  • Has track record of securing subsidies through joint research with government research institutions.
  • Exclusive supply rights maintained for some models via overseas patents.
  • In-house researchers involved in technology standardization at international conferences.
  • Contributes to formation of Fukuoka bio-park, influencing local economy.
  • Conducts in-house patent clearance for gene modification technologies.
  • Maintains technological superiority through collaboration with cutting-edge genome editing tool development companies.

Future Outlook

Growth Drivers

  • Increasing demand for research models due to advances in gene editing technology
  • Diversification of drug discovery modalities in the pharmaceutical industry
  • Growing bio-service demand from expanded domestic and international research investments
  • Increasing demand for high-quality models from heightened animal welfare awareness
  • Expansion of technology consulting demand
  • Operational efficiency gains through digital transformation
  • Expansion of model animal provision to overseas markets
  • Improved reliability through green sustainability compliance
  • Rapid response to strengthened scientific research regulations
  • Activation of industry-academia-government collaboration projects
  • Increasing support for personalized medicine technologies in drug discovery
  • Improved gene analysis efficiency through AI technology utilization

Strategic Goals

  • Achieve top domestic market share in outsourced model production
  • Develop innovative services in gene modification technology
  • Strengthen global business expansion through overseas base establishment
  • Obtain animal welfare certification at all business sites
  • Achieve internal sustainability goals
  • Double sales of technology consulting services
  • Full automation of business processes through DX promotion
  • Market expansion through provision of wide-ranging disease models
  • Increase number of joint developments with diverse research institutions
  • Establish global standard compliant system

Business Segments

Gene Analysis Outsourcing

Overview
Provides model production and outsourced analysis services utilizing advanced gene modification technologies to meet drug discovery development and basic research needs.
Competitiveness
High expertise in gene editing technology and rapid response capabilities
Customers
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Universities/Research Institutions
  • Public Research Institutions
  • Medical Institutions
  • Academia
Products
  • Transgenic Mouse Production
  • Gene Editing Model Provision
  • Model Animal Pathophysiology Analysis
  • Pharmacological Evaluation Outsourcing
  • Gene Analysis Service
  • Phenotype Analysis
  • Humanized Model Development

Research Equipment & Reagent Sales

Overview
Sells equipment and reagents necessary for gene manipulation and cell culture, contributing to research site support and quality maintenance.
Competitiveness
Lineup of specialized products optimized for transgenic technology
Customers
  • Research Institutes
  • Universities
  • Pharmaceutical Companies
  • Outsourced Analysis Companies
  • Bio-Related Startups
Products
  • CRISPR Editing Kit
  • Cell Culture Reagents
  • Gene Introduction Equipment
  • Husbandry Feed
  • Various Reagents

Technology Consulting

Overview
Provides technology support and consulting related to gene editing and model animal production to support research and development success.
Competitiveness
Practical support by staff with extensive specialized knowledge
Customers
  • New Entrant Companies
  • University Labs
  • Pharmaceutical Company R&D Departments
  • Bio Startups
  • Government Agencies
Products
  • Model Design Advice
  • Gene Editing Plan Support
  • Experimental Plan Consulting
  • Technology Training
  • Patent Research Support

Outsourced Animal Husbandry Management

Overview
Outsourced husbandry management of experimental animals to maintain high-quality model utilization environments.
Competitiveness
Strict animal welfare compliance and specialized technology
Customers
  • Bio Companies
  • Universities
  • Pharmaceutical Manufacturers
  • Contract Testing Institutions
  • Research Facilities
Products
  • Model Animal Colony Management
  • Husbandry Environment Optimization
  • Animal Welfare Management
  • Long-term Husbandry Support
  • Pathophysiology Monitoring

Drug Discovery Research Support Services

Overview
Provides models and analysis support in new drug development phases, contributing to drug discovery efficiency.
Competitiveness
High pathophysiology reproducibility model provision capability
Customers
  • Major Pharmaceutical Companies
  • Small/Medium Drug Discovery Ventures
  • Public Research Institutions
  • Hospital-Affiliated Institutes
  • Japan Science and Technology Agency
Products
  • Pharmacological Evaluation Model Production
  • Drug Mechanism of Action Analysis
  • Toxicity Evaluation Models
  • Pathophysiology Simulation Models
  • New Biomarker Exploration Support

Gene-Related Technology Development

Overview
Advances cutting-edge gene technology research and development to create future services and product deployments.
Competitiveness
Continuous promotion of technological innovation
Customers
  • Gene Therapy Companies
  • Advanced Bio Research Institutions
  • Medical Device Manufacturers
  • Bioinformatics Companies
  • University-Spinoff Ventures
Products
  • New Gene Editing Tool Development
  • Gene Introduction Technology Optimization
  • High-Sensitivity Gene Detection Technology
  • Cell Function Analysis Technology
  • Biosensor Development

Competitive Advantage

Strengths

  • Expertise in advanced gene modification technology
  • Efficient operations leveraging regional characteristics of Fukuoka base
  • Extensive model animal lineup
  • Customer-oriented contract service system
  • Rapid adoption of latest technologies
  • Research environment considerate of animal welfare
  • Strong collaborations with domestic and international research institutions
  • Comprehensive provision of diverse outsourced analyses
  • Established stable revenue base
  • Proprietary gene modification know-how
  • Advanced technical skills of specialized staff
  • High-quality colony management system
  • Competitive pricing
  • Long-term customer trust relationships
  • Flexible customization response

Competitive Advantages

  • Domestic top-class technology in gene-modified mouse production
  • Wide range of modification technologies to meet diverse research needs
  • Low cost and high quality achieved with Fukuoka base
  • Rapid delivery and flexible service design
  • Comprehensive provision of advanced research support services
  • Customer base expansion through strong academic-industry network
  • Improved reliability through animal welfare standard compliance
  • Specialized model provision for diverse research areas
  • High management quality of experimental animals via dedicated facilities
  • Introduction of cloud-based customer management system
  • Integrated system from contract research to technology development
  • Strong linkage with gene analysis services
  • Brand strength from numerous academic paper publications
  • Thorough regulatory compliance and information management
  • Corporate culture promoting sustained innovation

Threats

  • Risk of reduced outsourcing demand due to in-house production by large pharmaceutical companies
  • Entry of new biotech startups as competitors
  • Risk of cost increases due to stricter regulations
  • Need to adapt to rapid changes in gene editing technology
  • Intensifying competition with overseas companies
  • Increased operational burden from further stringent animal welfare standards
  • Customer budget reductions due to research funding cuts
  • Demand instability due to social changes like new infectious diseases
  • Increased procurement costs for equipment and reagents from exchange rate fluctuations
  • Risks of patent disputes and technology leakage
  • Intensified talent acquisition competition
  • Risks to biological sample logistics from natural disasters

Innovations

2023: High-Speed Mouse Model Development Using CRISPR Technology

Overview
Established gene-modified mouse production technology with 60% shorter timeframe than conventional methods.
Impact
Achieved reduction in research and development period and costs

2022: Advanced Humanized Immune System Mouse Models

Overview
Developed humanized immune system models with higher clinical relevance, contributing to drug discovery research.
Impact
Increased expectations for improved drug discovery success rates

2024: Introduction of Animal Welfare Compliant Husbandry System

Overview
Introduced stress-reducing husbandry environments and monitoring systems to strengthen ethical standards.
Impact
Achieved regulatory compliance and enhanced customer trust

2021: Research and Development of Gene Expression Control Tools

Overview
Initiated research on new technology capable of controlling gene expression timing and locations.
Impact
Enables more precise model production

2020: Introduction of Cloud-Based Contract Management System

Overview
Implemented online management of contract projects for improved efficiency and transparency.
Impact
Improved customer satisfaction and operational efficiency

Sustainability

  • Thorough compliance with animal welfare standards in husbandry management
  • Promotion of renewable energy introduction (30% by 2025)
  • Strengthened waste reduction and recycling initiatives
  • Participation in environmental conservation activities through regional collaboration
  • Introduction of low-environmental-impact experimental equipment